Scientists have recently made an important discovery that could potentially revolutionize cancer treatment. Researchers from the Cancer Research UK Scotland Institute and Memorial Sloan Kettering Cancer Center in the U.S. have found that cancer patients with defective mitochondria, the energy factories found in every living cell, are up to two-and-a-half times more likely to respond to currently available cancer drugs.
In their study, titled “Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade in melanoma,” published in the journal Nature Cancer, the scientists demonstrate a direct link between mitochondrial DNA (mtDNA) mutations and the response to cancer treatment. They discovered that tumors with high levels of mtDNA mutations have a greater chance of responding positively to immunotherapy drugs such as nivolumab, which release a brake on the immune system to attack cancer cells.
Immunotherapy is a type of treatment that utilizes the body’s natural defenses to fight against cancer. By testing for mitochondrial DNA mutations, doctors could identify patients who are more likely to benefit from immunotherapy before starting the treatment. This groundbreaking discovery opens up new possibilities for personalized cancer treatment, as it allows doctors to tailor therapies to individual patients based on their mitochondrial DNA status.
Currently, half of all cancers have mitochondrial DNA mutations, making this discovery even more significant. By exploiting these mutations, scientists believe that they can improve the effectiveness of cancer treatment. The researchers also suggest that combining treatments that mimic the effects of these mutations with immunotherapy could greatly enhance the chances of successful treatment for a wider range of cancer types.
The findings from this study have led to the filing of patents by Cancer Research Horizons, the innovation arm of Cancer Research UK. These patents aim to bring the technology behind the discovery to market, enabling the development of new treatments that disrupt the energy sources cancer relies on to spread and grow. Cancer Research Horizons has a successful track record of bringing innovative cancer drugs to market, having already introduced 11 new drugs that have been used in over six million courses of cancer treatment worldwide.
Dr. Payam Gammage, Group Leader at the Cancer Research UK Scotland Institute and the University of Glasgow, and co-lead author of the study, commented on the potential impact of this discovery: “Cancer is a disease of our own bodies. Because cancer cells can look similar to healthy cells on the outside, getting our immune systems to recognize and destroy cancer cells is a complicated task.” By identifying the link between mitochondrial DNA mutations and the effectiveness of immunotherapy, this research brings us one step closer to overcoming this challenge.
The implications of this discovery are significant as it paves the way for more targeted and effective cancer treatment. By understanding the role of mitochondrial DNA mutations in determining cancer response to immunotherapy, doctors can improve patient outcomes by selecting the most suitable treatment option. With further research and development, this breakthrough may transform the way we approach cancer treatment and bring hope to millions of patients worldwide.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it